Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Current Deferred Revenue: 2014-2025

Historic Current Deferred Revenue for BIO-TECHNE (TECH) over the last 11 years, with Sep 2025 value amounting to $32.7 million.

  • BIO-TECHNE's Current Deferred Revenue rose 11.99% to $32.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.7 million, marking a year-over-year increase of 11.99%. This contributed to the annual value of $35.3 million for FY2025, which is 16.89% up from last year.
  • According to the latest figures from Q3 2025, BIO-TECHNE's Current Deferred Revenue is $32.7 million, which was down 7.37% from $35.3 million recorded in Q2 2025.
  • BIO-TECHNE's Current Deferred Revenue's 5-year high stood at $35.6 million during Q1 2025, with a 5-year trough of $19.7 million in Q1 2021.
  • Over the past 3 years, BIO-TECHNE's median Current Deferred Revenue value was $30.2 million (recorded in 2024), while the average stood at $30.2 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first soared by 50.00% in 2021, then decreased by 3.53% in 2023.
  • Quarterly analysis of 5 years shows BIO-TECHNE's Current Deferred Revenue stood at $20.8 million in 2021, then grew by 12.98% to $23.5 million in 2022, then climbed by 28.09% to $30.1 million in 2023, then grew by 1.00% to $30.4 million in 2024, then increased by 11.99% to $32.7 million in 2025.
  • Its Current Deferred Revenue was $32.7 million in Q3 2025, compared to $35.3 million in Q2 2025 and $35.6 million in Q1 2025.